{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:09:44Z","timestamp":1788905384685,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.transci.2026.104523","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:08:48Z","timestamp":1788390528000},"page":"104523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlations between autograft cellular components and post-transplant outcome in patients with systemic non-Hodgkin lymphoma mobilized with on-demand plerixafor: A prospective multicenter GOA study"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-2582","authenticated-orcid":false,"given":"Anu","family":"Partanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Turunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Varmavuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Jantunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.transci.2026.104523_bib1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.bmt.1704466","article-title":"Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma","volume":"33","author":"Kuittinen","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.transci.2026.104523_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1600-0609.2010.01520.x","article-title":"Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies","volume":"85","author":"Jantunen","year":"2010","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.transci.2026.104523_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.transci.2026.104523_bib4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/bmt.2010.320","article-title":"Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens","volume":"46","author":"Jantunen","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.transci.2026.104523_bib5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00277-012-1411-8","article-title":"Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use","volume":"91","author":"Jantunen","year":"2012","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.transci.2026.104523_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jca.21550","article-title":"Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: a systematic review and meta-analysis","volume":"32","author":"Kuan","year":"2017","journal-title":"J Clin Apher"},{"issue":"9","key":"10.1016\/j.transci.2026.104523_bib7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1517\/14712598.2011.601737","article-title":"Novel strategies for blood stem cell mobilization: special focus on plerixafor","volume":"11","author":"Jantunen","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"10.1016\/j.transci.2026.104523_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17474086.2016.1208082","article-title":"Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma","volume":"9","author":"Jantunen","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"10.1016\/j.transci.2026.104523_bib9","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1111\/trf.18033","article-title":"Comparison of the efficacy of a generic plerixafor versus Mozobil as adjunct peripheral blood stem cell mobilization agents in multiple myeloma patients","volume":"64","author":"Yuan","year":"2024","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.transci.2026.104523_bib10","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/j.1537-2995.2012.03579.x","article-title":"Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis","volume":"52","author":"Costa","year":"2012","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.transci.2026.104523_bib11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/trf.13141","article-title":"A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the \"on-demand\" scheme of administration at French autologous hematopoietic stem cell transplant programs","volume":"55","author":"Chabannon","year":"2015","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.transci.2026.104523_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jcyt.2024.12.007","article-title":"Autograft composition and outcome-towards an optimal graft?","volume":"27","author":"Jantunen","year":"2025","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.transci.2026.104523_bib13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/trf.17755","article-title":"Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation","volume":"64","author":"Jantunen","year":"2024","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.transci.2026.104523_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14653240310000083","article-title":"Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study","volume":"5","author":"Gratama","year":"2003","journal-title":"Cytotherapy"},{"key":"10.1016\/j.transci.2026.104523_bib15","unstructured":"http:\/\/cibmtr.org."},{"issue":"3","key":"10.1016\/j.transci.2026.104523_bib16","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.transci.2026.104523_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.12606","article-title":"Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs","volume":"164","author":"Milone","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.transci.2026.104523_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jca.21496","article-title":"Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure","volume":"32","author":"Worel","year":"2017","journal-title":"J Clin Apher"},{"issue":"7","key":"10.1016\/j.transci.2026.104523_bib19","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"28","key":"10.1016\/j.transci.2026.104523_bib20","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.transci.2026.104523_bib21","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.bbmt.2018.01.039","article-title":"Plerixafor plus granulocyte colony-stimulating factor for patients with non-hodgkin lymphoma and multiple myeloma: long-term follow-up report","volume":"24","author":"Micallef","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.transci.2026.104523_bib22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/1042819031000067585","article-title":"Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation","volume":"44","author":"Gordan","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.transci.2026.104523_bib23","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1007\/s00277-025-06686-3","article-title":"Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk","volume":"104","author":"Duminuco","year":"2025","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.transci.2026.104523_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.transci.2026.104523_bib25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41409-019-0693-z","article-title":"Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor","volume":"55","author":"Sureda","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.transci.2026.104523_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103830","article-title":"Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection","volume":"62","author":"Lanza","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"10.1016\/j.transci.2026.104523_bib27","doi-asserted-by":"crossref","first-page":"769.e1","DOI":"10.1016\/j.jtct.2021.05.026","article-title":"Infused autograft absolute lymphocyte count predicts superior survival in diffuse large B cell lymphoma patients post-autologous peripheral blood hematopoietic stem cell transplantation: a matched case-control study","volume":"27","author":"Porrata","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.transci.2026.104523_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcyt.2013.03.013","article-title":"Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone","volume":"15","author":"Gaugler","year":"2013","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.transci.2026.104523_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2024.103931","article-title":"Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose","volume":"63","author":"Lanza","year":"2024","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"10.1016\/j.transci.2026.104523_bib30","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/trf.14182","article-title":"Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes","volume":"57","author":"Worel","year":"2017","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.transci.2026.104523_bib31","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1111\/trf.13170","article-title":"Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison","volume":"55","author":"Valtola","year":"2015","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.transci.2026.104523_bib32","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1080\/10428194.2020.1762879","article-title":"Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study","volume":"61","author":"Turunen","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.transci.2026.104523_bib33","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/j.clml.2023.08.009","article-title":"Loss of CD34+ cells and effect of the number of viable cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery, progression-free survival and overall survival in NHL patients after autologous stem cell transplantation","volume":"23","author":"Partanen","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.transci.2026.104523_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3816\/CLM.2007.n.009","article-title":"AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma","volume":"7","author":"Holtan","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"issue":"14","key":"10.1016\/j.transci.2026.104523_bib35","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3390\/cancers16142550","article-title":"Predictive factors for early immune recovery in NHL patients after autologous transplantation: a multicenter prospective study","volume":"16","author":"Partanen","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.transci.2026.104523_bib36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14653240802165665","article-title":"The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma","volume":"10","author":"Hiwase","year":"2008","journal-title":"Cytotherapy"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226001552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050226001552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:38:53Z","timestamp":1788903533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050226001552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1473050226001552"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2026.104523","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlations between autograft cellular components and post-transplant outcome in patients with systemic non-Hodgkin lymphoma mobilized with on-demand plerixafor: A prospective multicenter GOA study","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2026.104523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104523"}}